Simulations Plus, Inc. provides model-informed and AI-accelerated drug development software, training, and consulting services for biopharmaceutical research. News about the company centers on its software and services segments, scientific modeling engines, ADMET and other modeling workflows, and financial results tied to software renewals, services bookings, and customer activity.
Recurring developments also include collaborations with pharmaceutical companies, technology providers, and regulatory or public-health agencies. These updates cover GPU-accelerated simulation, AI-assisted modeling, predictive frameworks for complex oral drug products, computational toxicology, new approach methodologies, and education programs that expand use of model-informed drug development practices.
Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at the BofA Securities 2021 Tech Solutions for Drug Discovery Conference on September 20, 2021, at 10:00 a.m. ET, and at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 22, 2021, at 9:55 a.m. ET. One-on-one meetings will also be held at both events. Live webcasts and presentations will be accessible via the Investors page of the Simulations Plus website for 90 days.
Simulations Plus (Nasdaq: SLP) announced promising results from the second phase of a collaborative research project with a major pharmaceutical company. Nearly 30% of the 19 synthesized molecules demonstrated activity below 50 nM, indicating strong therapeutic potential. The predictive errors in rat and human microsomal clearance were improved by three-fold, showcasing advancements in the Artificial Intelligence-driven Drug Design (AIDD) Module of ADMET Predictor. The company plans to present further details in the coming months, along with functional updates to be released this fall.
Simulations Plus, Inc. (Nasdaq: SLP) has received a significant order from China's National Medical Products Administration (NMPA) to add licenses for its GastroPlus® software. This development underscores the growing adoption of physiologically based biopharmaceutics modeling in drug development. Division president John DiBella highlighted the expanding relationships with the NMPA and the positive impact on over 20 domestic Chinese pharmaceutical companies. The initiative aims to enhance regulatory review processes, potentially reducing time to market for new medicines, benefiting both companies and patients.
Simulations Plus, Inc. (Nasdaq: SLP) reported its third quarter fiscal 2021 results with total revenue of $12.8 million, up 4% year-over-year. Software revenue surged 21% to $8.3 million, while services revenue dropped 18% to $4.5 million. Gross profit rose 7% to $10.3 million, and net income increased 29% to $3.8 million. For the year-to-date, total revenue grew 14% to $36.6 million, bolstered by a 32% rise in software revenue. Despite project delays in services, the company anticipates full-year revenue growth of 5-10%.
Summary not available.
Simulations Plus, Inc. (Nasdaq: SLP) announced it will release its financial results for Q3 of fiscal year 2021, ending May 31, 2021, on July 12, 2021, after market close. A conference call is scheduled for the same day at 4:15 p.m. Eastern Time, where stakeholders can register to participate. Simulations Plus has been a leader in modeling and simulation software for drug development and has served clients for over 25 years, providing solutions to major pharmaceutical and regulatory agencies globally.
Simulations Plus (Nasdaq: SLP) announced the release of IPFsym version 1A, a quantitative systems pharmacology software aimed at developing treatments for idiopathic pulmonary fibrosis (IPF). The software, sponsored by a leading pharmaceutical company, aims to enhance treatment options in a market worth over $2 billion. Key features include a virtual population of over 700 subjects and important biomarkers like forced vital capacity and high-resolution computed tomography. The company will also host a webinar for further insights on IPFsym.
Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will participate in the Craig-Hallum 18th Annual Institutional Investor Conference on June 2, 2021. The conference will be virtual, featuring over 150 public companies and allowing institutional clients to engage in one-on-one 30-minute meetings. Attendance is by invitation only. Simulations Plus has been a leading provider of simulation software and consulting services for drug discovery for 25 years, serving clients across the globe.
Simulations Plus (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at the 16th Annual Needham Virtual Technology and Media Conference on May 20, 2021, at 1:30 p.m. ET. CFO Will Frederick will also participate in one-on-one meetings throughout the day. This conference will feature presentations from over 350 public and private company management teams, providing an excellent opportunity for shareholders and investors.
For inquiries or to schedule meetings, contact Hayden IR at slp@haydenir.com. More details can be found on the Needham conference website.
Simulations Plus, Inc. (Nasdaq: SLP) announced that its common stock has been approved for trading on The Nasdaq Global Select Market effective May 13, 2021. This milestone reflects the company's successful growth investments that have enhanced its financial performance and global scale. CEO Shawn O’Connor highlighted that this step will increase visibility and liquidity for existing and future shareholders. Simulations Plus has been providing modeling and simulation solutions for over 25 years, serving clients in pharmaceutical and biotechnology sectors.